COMPARISON
Glucagon vs Octreotide
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Octreotide in 10 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Octreotide: highest phase Phase 4 (after approval). 12 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Octreotide | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 344 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Octreotide Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2025-06-30 ema · 2026-10-03 |
| EU withdrawn on differs | Not checked no record of "withdrawnOn" for glucagon | 2022-12-02 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | H01CB02 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Glucagon | placebo | Octreotide | placebo |
|---|---|---|---|---|
| Diarrhoea | - | - | 46.2% | 31.7% |
| Oedema peripheral | - | - | 34.9% | 19.6% |
| Asthenia | - | - | 33.3% | 20.9% |
| Nausea | - | - | 30.8% | 21.2% |
| Fatigue | - | - | 29.8% | 27.7% |
| Rash | - | - | 28.8% | 14.1% |
| Decreased appetite | - | - | 28.5% | 15.2% |
| Hypertension | - | - | 26.5% | 19.4% |
| Dyspnoea | - | - | 25.9% | 9.1% |
| Anaemia | - | - | 24.3% | 9.1% |
Trial register Glucagon: 2 placebo-controlled trials; Octreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Glucagon side effects · Octreotide side effects
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Octreotide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
12 registered trials include both
| NCT06592261 | Graded Insulin Suppression Test P&F RECRUITING · updated 2026-09-08 |
|---|---|
| NCT06240039 | Direct Versus Indirect Effect of Amino Acids on Hepatokines ACTIVE_NOT_RECRUITING · updated 2026-05-07 |
| NCT06558422 | Human Models of Selective Insulin Resistance: Pancreatic Clamp NOT_YET_RECRUITING · updated 2026-02-06 |
| NCT05724134 | Pancreatic Clamp in NAFLD COMPLETED · updated 2026-01-12 |
| NCT06126354 | Dexamethasone/Pancreatic Clamp P&F WITHDRAWN · updated 2024-07-10 |
| NCT02381249 | The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery COMPLETED · updated 2023-11-27 |
| NCT02385617 | Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer COMPLETED · updated 2023-11-27 |
| NCT03103009 | Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia COMPLETED · updated 2021-09-29 |
| NCT01865760 | Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia COMPLETED · updated 2019-10-28 |
| NCT03057509 | A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors WITHDRAWN · updated 2019-06-21 |
| NCT02237053 | Effects of Glucagon Administration on Energy Expenditure COMPLETED · updated 2018-04-26 |
| NCT02012166 | A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insul COMPLETED · updated 2015-08-19 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.